Table 2 Baseline biomarker and patient characteristics by treatment assignment
PCI (N = 37) | MED (N = 33) | ||||
|---|---|---|---|---|---|
n | % (mean ± sd) median{interquartile range}* | n | % (mean ± sd) median{interquartile range}* | p-value | |
Biomarkers | |||||
Baseline NT-proBNP(ng/L){IQR} | 37 | 846.1{402.4,1488} | 33 | 1100{474.6,1726} | 0.306 |
Baseline VEGF(pg/mL){IQR} | 31 | 42.5{23.6,207.2} | 27 | 37.5{17.4,70.2} | 0.293 |
Baseline MMP-2(ng/mL){IQR} | 33 | 185.7{172.3,216.9} | 28 | 185.3{172.1,239.7} | 0.879 |
Baseline MMP-9(ng/mL){IQR} | 33 | 90{56,185} | 28 | 102.3{44.2,163.2} | 0.506 |
Baseline TIMP-2(ng/mL){IQR} | 33 | 64.5{57.6,74.1} | 28 | 64.3{59.2,70} | 0.789 |
Baseline GALECTIN(ng/L){IQR} | 33 | 12.8{9.8,15.5} | 28 | 13{9.2,14.9} | 0.806 |
Age (years) | 37 | (62.5 ± 9.1) | 33 | (58.8 ± 8.1) | 0.086 |
Female | 11 | 29.7 | 6 | 18.2 | 0.261 |
Race White | 37 | 100 | 33 | 100 | . |
Clinical History | |||||
Angina | 8 | 21.6 | 7 | 21.2 | 0.967 |
Myocardial infarction | 1 | 2.7 | 2 | 6.1 | 0.599 |
Percutaneous coronary intervention | 3 | 8.1 | 1 | 3 | 0.616 |
Congestive heart failure | 0 | 0 | 1 | 3 | 0.471 |
Hypertension | 21 | 56.8 | 15 | 45.5 | 0.345 |
Diabetes | 2 | 5.4 | 8 | 24.2 | 0.038 |
Insulin use | 1 | 2.7 | 5 | 15.2 | 0.093 |
Hypercholesterolemia | 15 | 40.5 | 16 | 48.5 | 0.504 |
Stroke | 2 | 5.4 | 2 | 6.1 | 1.000 |
Cerebrovascular disease | 2 | 5.4 | 3 | 9.1 | 0.661 |
Peripheral vascular disease | 1 | 2.7 | 0 | 0 | 1.000 |
Current Smoker | 13 | 35.1 | 12 | 36.4 | 0.915 |
Family history CAD | 12 | 32.4 | 17 | 51.5 | 0.106 |
Days from MI to randomization - median {IQR} | 37 | 22{17–26} | 33 | 20{14–25} | 0.135 |
Index myocardial infarction | |||||
Received thrombolytics | 1 | 2.7 | 0 | 0 | 1.000 |
STE / Q wave / R loss | 30 | 81.1 | 28 | 84.8 | 0.676 |
Killip Class II-IV | 7 | 18.9 | 4 | 12.1 | 0.522 |
Ejection fraction | 37 | (46.8 ± 9) | 33 | (45.7 ± 10.5) | 0.652 |
Rales | 0 | 0 | 1 | 3.1 | 0.464 |
Clinical measures | |||||
Estimated GFR <60 ml/min/1.73 m2 | 5 | 13.5 | 3 | 9.1 | 0.714 |
Glucose > =126 mg/dl | 2 | 5.6 | 6 | 18.2 | 0.140 |
BMI (kg/m2) | 37 | (26.4 ± 2.8) | 32 | (27.2 ± 4.3) | 0.365 |
Heart rate (bpm) | 37 | (68.9 ± 9.4) | 33 | (69.7 ± 10.3) | 0.733 |
Systolic blood pressure (mmHg) | 37 | (119.5 ± 11.4) | 33 | (121.4 ± 12.5) | 0.507 |
Angiography | |||||
Infarct-related artery (IRA) LAD | 13 | 35.1 | 6 | 18.2 | 0.240 |
Infarct-related artery (IRA) Lcx | 6 | 16.2 | 5 | 15.2 | |
Infarct-related artery (IRA) RCA | 18 | 48.6 | 22 | 66.7 | |
Angiography - multivessel disease | 9 | 24.3 | 12 | 37.5 | 0.236 |
Collaterals | 36 | 97.3 | 28 | 87.5 | 0.175 |
Medications | |||||
Aspirin | 36 | 97.3 | 32 | 97 | 1.000 |
Thienopyridine | 34 | 91.9 | 8 | 24.2 | <.001 |
Warfarin | 0 | 0 | 3 | 9.1 | 0.100 |
Beta blocker | 32 | 86.5 | 33 | 100 | 0.056 |
Ca blocker | 1 | 2.7 | 1 | 3 | 1.000 |
Lipid lowering agent | 35 | 94.6 | 33 | 100 | 0.494 |
Spironolactone | 6 | 16.2 | 3 | 9.1 | 0.485 |
ACE-Inhibitor or ARB | 32 | 86.5 | 30 | 90.9 | 0.714 |